EANM 2025 | C-Ray’s ²²⁵Ac Studies Featured as Top Oral Presentations at EANM 2025.
From October 4th to 8th, 2025, the global nuclear medicine community will gather in Barcelona, Spain, for the highly anticipated annual event—the European Association of Nuclear Medicine (EANM) Annual Congress 2025. This year's congress is particularly significant as it marks the 40th anniversary of EANM's founding.
C-Ray Therapeutics will actively participate in this milestone event by presenting multiple innovative achievements. Through cutting-edge academic presentations, interactive booth exchanges, and a relaxed Happy Hour networking event, we look forward to engaging with global experts and scholars to discuss the future of nuclear medicine.
C-Ray Therapeutics is evolving from an active participant into a contributor of innovative solutions and a driver of industry dialogue, increasingly integrating into the global advancement of nuclear medicine. We sincerely invite all colleagues to visit us at Booth #123 in Barcelona. Let's join hands to explore cutting-edge technologies and foster the growth of our field together.
01
Academic Spotlight
Two Studies Selected as Top Rated Oral Presentations
Two studies on ²²⁵Ac-PSMA-CY313 in the field of metastatic castration-resistant prostate cancer (mCRPC), supported by C-Ray Therapeutics, have been highly recognized by the Congress Review Committee for their innovation and significant value. They have been selected as "Top Rated Oral Presentations". This achievement signifies that China's exploration in the forefront of radiopharmaceuticals is gaining increasing international attention.
We cordially invite you to attend the following two sessions to learn about the latest data and engage with our team of scientists：
Presentation 1: Feasibility Exploration in Dosimetry Study
Title:Feasibility study of 225Ac-PSMA-CY313 dosimetry in mCRPC patients using SPECT
Session：Cutting Edge Science Track - Quantification and Innovation in Dosimetry
Abstract No：OP-594
Venue：Room 211
Date & Time：Tuesday, October 7, 9:45 - 11:15
Presentation 2: Preliminary Results on Efficacy and Safety
Title：Evaluation of the safety and efficacy of 225Ac-PSMA-CY313 in metastatic castration-resistant prostate cancer: preliminary results
Session：Theranostics Track - Prostate Cancer Therapy: Novel Probes
Abstract No：OP-671
Venue：Room 117
Date & Time：Tuesday, October 7, 15:00 - 16:30
02
Exhibition Booth Engagement
On-site Connection for One-Stop CRDMO Solutions
During the conference, we will have a dedicated engagement area at Booth #123. Here, you will have the opportunity for face-to-face discussions with C-Ray Therapeutics' technical and business teams. Gain in-depth insights into our comprehensive service capabilities, which encompass process development, quality research, preclinical evaluation, IND application support, as well as clinical supply and commercial cGMP manufacturing.
We will particularly highlight our core strengths in the supply assurance of α-emitters (such as Ac-225) and other scarce isotopes, as well as our dedicated R&D platforms.
03
Happy Hour
Unwind, Connect, and Shape the Future Together
To foster more relaxed industry dialogue, we will host the "C-Ray Happy Hour" networking event during the congress.
With a selection of fine drinks and authentic Spanish tapas, we warmly welcome both existing and new partners to join us. Let’s share insights and collaborate in the autumn ambiance of Barcelona, as we collectively chart the future of nuclear medicine.
Time: October 5, 2025 (Sunday) 16:00 - 18:00
Location: C-Ray Therapeutics Booth (Booth #123)
For more exciting updates on our global activities, feel free to scan the QR code below to follow our LinkedIn account ⬇️
Introduction to C-Ray Therapeutics
C-Ray Therapeutics is dedicated to delivering end-to-end solutions for innovative radiopharmaceuticals to clients around the world. Our services span process development, quality research, preclinical evaluation, IND Enabling, clinical supply, and commercial scale cGMP production, all backed by a reliable, robust logistics network. As of 2024, we have raised over USD 187 million in total funding.
As a dedicated CRDMO partner in radiopharmaceuticals, one of our core strengths is a stable, diversified supply of radionuclides. We are actively developing high-quality domestic sources while playing a leading role in integrating and fortifying the global supply chain—most notably securing access to challenging isotopes such as Ac-225. To date, we have supported the development of 14 Ac-225–labeled projects.
Committed to empowering the industry, C-Ray Therapeutics is building an open, integrated “production–academia–research–application” platform. By pooling resources across the value chain and pioneering critical radiopharmaceutical technologies, we accelerate the clinical translation of integrated diagnostic & therapeutic solutions. Our goal is to drive innovation and industrial upgrading in the radiopharmaceutical sector, establishing ourselves as a global benchmark in the field.
